Partnerships Critical To Building China’s R&D Ecosystem (Pt.2)
This article was originally published in PharmAsia News
Executive Summary
Foreign pharmaceutical companies often have to wait years to bring new drugs to China due to the country’s lengthy approval process, and are expressing concerns that such regulatory delays could push back by several years plans to introduce their latest drugs.